Ocular Therapeutix (OCUL) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is OCUL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript…

Maintaining a "Buy" on Ocular Therapeutix, supported by FDA alignment on the AXPAXLI wet-AMD filing and opportunities to extend dosing and indications. The company expects Q4 2026 SOL-R 52-week interim safety data and an…

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript…

Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said on the company's third…

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.…

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on subm…

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced…

Ocular Therapeutix (NASDAQ: OCUL - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses b…

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to…

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in…

Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expe…

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript…

Ocular Therapeutix NASDAQ: OCUL is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with th…

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to f…

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in…

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment w…

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announce…

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission fo…

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation i…

BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in a recent quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of the biopharmaceutical com…

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

